First-line immunotherapy for non–small-cell lung cancer
M Reck, J Remon, MD Hellmann - Journal of Clinical Oncology, 2022 - ingentaconnect.com
For patients with metastatic non–small-cell lung cancer (mNSCLC), the last decade has
been characterized by critical progress that has contributed to substantially improved …
been characterized by critical progress that has contributed to substantially improved …
The next decade of immune checkpoint therapy
P Sharma, BA Siddiqui, S Anandhan, SS Yadav… - Cancer discovery, 2021 - AACR
Immune checkpoint therapy (ICT) can provide durable clinical responses and improve
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
overall survival. However, only subsets of patients with specific tumor types respond to ICT …
Lineage plasticity in prostate cancer depends on JAK/STAT inflammatory signaling
Drug resistance in cancer is often linked to changes in tumor cell state or lineage, but the
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
molecular mechanisms driving this plasticity remain unclear. Using murine organoid and …
CD8+ T cell states in human cancer: insights from single-cell analysis
AM Van der Leun, DS Thommen… - Nature Reviews …, 2020 - nature.com
The T cell infiltrates that are formed in human cancers are a modifier of natural disease
progression and also determine the probability of clinical response to cancer …
progression and also determine the probability of clinical response to cancer …
Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
J Gao, N Navai, O Alhalabi, A Siefker-Radtke… - Nature medicine, 2020 - nature.com
Immune checkpoint therapy is being tested in the neoadjuvant setting for patients with
localized urothelial carcinoma,, with one study reporting data in cisplatin-ineligible patients …
localized urothelial carcinoma,, with one study reporting data in cisplatin-ineligible patients …
A genetic mouse model recapitulates immune checkpoint inhibitor–associated myocarditis and supports a mechanism-based therapeutic intervention
Immune checkpoint inhibitors (ICI) targeting CTLA4 or PD-1/PD-L1 have transformed cancer
therapy but are associated with immune-related adverse events, including myocarditis …
therapy but are associated with immune-related adverse events, including myocarditis …
Dissecting the mechanisms of immune checkpoint therapy
P Sharma, JP Allison - Nature Reviews Immunology, 2020 - nature.com
Immune checkpoint therapy with antibodies targeting CTLA4 or PD1/PDL1 has led to
durable regression of disease and cures for a subset of patients with cancer, which has led …
durable regression of disease and cures for a subset of patients with cancer, which has led …
Gut CD4+ T cell phenotypes are a continuum molded by microbes, not by TH archetypes
Abstract CD4+ effector lymphocytes (Teff) are traditionally classified by the cytokines they
produce. To determine the states that Teff cells actually adopt in frontline tissues in vivo, we …
produce. To determine the states that Teff cells actually adopt in frontline tissues in vivo, we …
Inherited PD-1 deficiency underlies tuberculosis and autoimmunity in a child
The pathophysiology of adverse events following programmed cell death protein 1 (PD-1)
blockade, including tuberculosis (TB) and autoimmunity, remains poorly characterized. We …
blockade, including tuberculosis (TB) and autoimmunity, remains poorly characterized. We …
Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies
Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such
as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) …
as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1) …